

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 March 2019 (14.03.2019)



(10) International Publication Number
WO 2019/051102 A2

(51) International Patent Classification:

C07K 16/18 (2006.01) C07K 16/30 (2006.01)
C07K 16/28 (2006.01) A61P 35/00 (2006.01)

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2018/049774

(22) International Filing Date:

06 September 2018 (06.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/555,943 08 September 2017 (08.09.2017) US
62/586,627 15 November 2017 (15.11.2017) US
62/587,318 16 November 2017 (16.11.2017) US

(71) Applicant: MAVERICK THERAPEUTICS, INC.

[US/US]; 3260 B Bayshore Blvd., 1st Floor, Brisbane, CA 94005 (US).

(72) Inventors: MAY, Chad; 1060 Continental Way, Apt. 303, Belmont, CA 94002 (US). DUBRIDGE, Robert, B.; 825 Holly Road, Belmont, CA 94002 (US). VINOGRADOVA, Maia; 2079 Ascot Drive, Unit 240, Moraga, CA 94556 (US). PANCHAL, Anand; 2615 Turk Street, Apt A., San Francisco, CA 94118 (US).

(74) Agent: SILVA, Robin, M. et al.; Mogan, Lewis, & Bockius LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS

(57) Abstract: The invention relates to Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

WO 2019/051102 A2